you attend the first study visit after joining the trial. during this visit a 7‑day heart rhythm recording (Holter‑ECG) is performed to measure the number of premature ventricular contractions (PVC) you have. you also complete questionnaires about your quality of life. after these assessments you are randomly assigned to receive either flecainide or bisoprolol as the study medication.

if you are assigned to the flecainide group, you take one oral tablet of flecainide 150 mg each day. if you are assigned to the bisoprolol group, you take one oral tablet of bisoprolol 2.5 mg each day. the medication is taken at the same time each day, with water, and you continue taking it for the entire three‑month treatment period.

throughout the three‑month period you keep a simple diary of any symptoms such as fatigue, dizziness, blurred vision, tremor, or feeling faint. you also note any episodes of fast heart rhythm or low heart rate. this information helps the study team evaluate safety.

after three months you return for a follow‑up visit. another 7‑day Holter‑ECG recording is done to compare the number of PVCs with the baseline measurement. you again complete the quality‑of‑life questionnaires (EQ‑5D visual analogue scale and SF‑12). the study staff reviews your symptom diary and checks for any adverse events, such as serious heart problems, hospitalizations, or minor issues like low blood pressure or heart‑rate slowing. if needed, the doctor discusses whether a catheter ablation procedure might be required.

after the three‑month assessments are finished, the study medication is stopped. all data collected during the trial are recorded for analysis. no further study‑specific visits are required unless your regular doctor advises otherwise.